Compare iShares MSCI Indonesia ETF (EIDO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Repligen Corporation Common Stock — how do they compare? iShares MSCI Indonesia ETF trades at $11.83 (market cap $398.15M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 28.4× iShares MSCI Indonesia ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Repligen Corporation Common Stock for 0 Days on average.
| EIDO | RGEN | |
|---|---|---|
Market Cap | $398.15M | $11.31B |
Volume | 3,087,911 | 1,216,919 |
52-Week High | $19.22 | $194.57 |
52-Week Low | $10.80 | $102.87 |
Typical Hold Time | 76 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.71, up 0.34% with bearish technical signals from moving averages and neutral oscillators. The ETF faces weak price action despite trading at a bargain valuation of 8.7x P/E. Recent news highlights foreign capital rotation away from Asian equities and Indonesia's limited benefit from commodity gains, with 44% financials weighting constraining growth potential.
Outlook remains cautious due to technical downtrend and sector concentration risks. The low valuation offers potential value, but persistent weak momentum and limited EPS growth of 5.9% temper upside. Key risks include dependence on financial sector performance and broader Asian market sentiment shifts.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
